ClinicalTrials.gg
RecruitingNCT07489625Updated Aug 14, 2026

Hydromorphone With Electroacupuncture and Ear Acupoint Pressing for Refractory Cancer Pain

An Early Phase 1 interventional study of Hydromorphone Hydrochloride Extended-Release Tablets and Electroacupuncture in Refractory Cancer Pain and Cancer Pain, sponsored by Qinghai Red Cross Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Qinghai Red Cross Hospital · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Cancer Pain with a site in China — 13 open to participants now, 13 under way, 1 of them phase 3. Cancer Pain · China.

Planned enrollment
21st of 24
30 · median 110
Started
2026
with 4 others
Phase 1
Only one
of the 31
Primary completion
2027-12
later than 8 of 12 live
Registered
27th of 31
by date

Among the 31 studies in Cancer Pain with a site in China, this one is the 21st largest by planned enrollment of the 24 interventional ones that give a count, is one of 5 that started in 2026, is the only one in phase 1, reaches primary completion later than 8 of the 12 other live ones, and was the 27th registered.

Cancer Pain

311 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.

Browse Cancer Pain studies →

Open to participants now

13 of the 31 studies in Cancer Pain with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 45 Cancer Pain studies recruiting now, 33 (73%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Cancer Pain with a site in China, or all of them as a file.
02

Study summary

This trial aims to address refractory cancer pain (RCP). It will explore the synergistic efficacy and safety of hydromorphone hydrochloride sustained-release tablets (HHST) combined with electroacupuncture (EA) and ear acupoint pressing beans (EAPB) for RCP. Key outcomes will include dynamic changes in Numerical Rating Scale (NRS) scores, proportions of patients with effective analgesia (≥30% NRS reduction from baseline) and marked remission (≥50% NRS reduction from baseline), daily HHST dosage, breakthrough pain (BP) frequency, and drug-related adverse events (AEs) graded by CTCAE 6.0.

Read the detailed description

This study is a prospective, single-arm clinical trial designed to address the therapeutic challenge of refractory cancer pain (RCP). It will systematically explore the synergistic therapeutic effect of hydromorphone hydrochloride sustained-release tablets (HHST) combined with electroacupuncture (EA) and ear acupoint pressing beans (EAPB). Through a clinical research design, the study will comprehensively evaluate the efficacy and safety of this combined regimen in relieving RCP.

The primary observational focus of the study will be the dynamic changes in the Numerical Rating Scale (NRS) scores of patients before and after treatment. Researchers will quantitatively analyze the proportion of patients achieving effective analgesia (defined as a ≥30% reduction in NRS score from baseline) and marked remission (defined as a ≥50% reduction in NRS score from baseline). Meanwhile, the study will monitor key indicators to verify the analgesic efficacy and safety of the combined regimen from multiple dimensions: the daily dosage of HHST, the frequency of breakthrough pain (BP) episodes, and drug-related adverse events (AEs). All AEs will be graded in accordance with the Common Terminology Criteria for Adverse Events, Version 6.0 (CTCAE 6.0).

03

Conditions studied

  • Refractory Cancer Pain
  • Cancer Pain

Browse trials for

Keywords

  • electroacupuncture
  • ear acupoint pressing beans
  • hydromorphone
  • refractory cancer pain
  • cancer pain
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who meet the diagnostic criteria for cancer ;
  2. Diagnosis of cancer pain;
  3. Aged 18 or 80 years;
  4. Expected survival period ≥3 months;
  5. Performance Status (KPS) score ≥30 and Quality of Life (QOL) score ≥20;
  6. No history of allergy to opioid analgesics;
  7. No intellectual or psychiatric disorders; normal comprehension ability,capable of cooperating with pain assessments and questionnaire completion;
  8. Provision of signed written .

Exclusion criteria

Exclusion Criteria:

  1. Patients with pain clearly unrelated to the tumor itself;
  2. Patients with pain relief after standardized pharmacological treatment;
  3. Patients aged under 18 years or over 80 years;
  4. Patients with an expected survival of less than 3 months;
  5. Patients with a Performance Status (KPS) score \< 30 or Quality of Life (QOL) score \< 20;
  6. Pregnant or lactating women;
  7. Patients with intellectual disability, mental or consciousness disturbance, who are unable to assess pain accurately or complete questionnaire surveys;
  8. Patients with needle phobia or extreme resistance to acupuncture treatment;
  9. Patients with to Semen Vaccariae (Wang Bu Liu Xing).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Combined Therapy Group

    Drug: Hydromorphone Hydrochloride Extended-Release Tablets · Procedure: Electroacupuncture · Procedure: Ear Acupoint Pressing Beans

Interventions

  • DrugHydromorphoneStudies of HydromorphoneHydromorphone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Extended-release hydromorphone hydrochloride tablets will be initiated at a dose converted from the total 24-hour opioid dose before treatment, rounded down to the nearest whole tablet, and administered orally once daily.Patients will be evaluated every 24 hours, and the dosage will be adjusted according to changes in pain intensity and Numerical Rating Scale (NRS) score.The dose will be maintained if the daily baseline pain NRS score is ≤3 and breakthrough pain occurs ≤2 times per day.If the daily baseline pain NRS score is \>3 or breakthrough pain occurs \>2 times per day, the dose may be titrated upward or downward based on adverse reactions. The dose will be titrated upward with an increment of 8 mg, and the interval between dose titrations shall be at least 2 days.

  • ProcedureElectroacupuncture

    Electroacupuncture will be performed at three specific points: Zusanli (ST36), Quchi (LI11), and Kunlun (BL60). Following needle insertion and deqi sensation, electrodes will be connected to an electroacupuncture device delivering 2Hz dense-disperse wave stimulation for 30 minutes. One treatment cycle lasts 7 days, and treatment will be administered once daily for a total of 14 days.

  • ProcedureEar Acupoint Pressing Beans

    Six auricular acupoints will be selected, including Shenmen, Subcortex, Sympathetic, Endocrine, Liver, and Kidney. Vaccaria seeds will be attached to these acupoints and gently pressed with fingers until the patient experiences a sensation of soreness and distension. For continuous stimulation, pressing will be performed 3-5 times daily, 1-2 minutes each time, for a duration of 3-5 days.

06

What researchers measure

Primary outcomes

  1. Comparison of changes in Numerical Rating Scale (NRS) pain score between baseline and post-treatment.

    Pain intensity will be measured by the Numerical Rating Scale (0-10).Primary endpoints:(1) Analgesic efficacy rate: proportion of patients with ≥30% reduction in NRS from baseline;(2) Significant relief rate: proportion with ≥50% reduction in NRS from baseline.Assessments will be conducted at baseline and at the end of the 2-week treatment.

    Time frame: 2 weeks

Secondary outcomes

  1. Comparison of the change in dosage of hydromorphone hydrochloride extended-release tablets during treatment.

    The initial dose will be the equivalent dose of hydromorphone hydrochloride sustained-release tablets converted from the total opioid dose administered in the previous 24 hours. The dose will be titrated upward or downward according to daily baseline pain intensity, frequency of breakthrough pain, and occurrence of adverse reactions.

    Time frame: 2 weeks

  2. Comparison of the daily frequency of breakthrough pain between baseline and post-treatment.

    Breakthrough cancer pain (BTcP) is defined as a transient exacerbation of pain that occurs suddenly while baseline cancer pain is relatively well controlled, either spontaneously or induced by specific triggers.The daily frequency of breakthrough cancer pain (BTcP) episodes will be observed in patients during the treatment period.

    Time frame: 2 weeks

  3. Adverse Drug Reactions

    This study will evaluate the incidence and severity of adverse reactions associated with hydromorphone hydrochloride sustained-release tablets during the treatment period.Adverse events will be graded in accordance with the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE 5.0).

    Time frame: 2 weeks

  4. Comparison of changes in health-related quality of life from baseline to post-treatment.

    Assessment using the European Quality of Life 5-Dimensions (EQ-5D) questionnaire.The EQ-5D is a standardized health-related quality of life instrument consisting of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.Each dimension has 3 response levels to describe the patient's functional status or health state.In addition, the EQ-5D includes a visual analogue scale (EQ-VAS) where patients rate their overall health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: 2 weeks

  5. Incidence of Adverse Reactions Associated with Electroacupuncture and Ear Acupoint Pressing Beans

    This study will evaluate the incidence, severity of adverse reactions related to electroacupuncture and auricular point pressing therapy, as well as treatment compliance during the treatment period. Adverse events will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

    Time frame: 2 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Mar 24, 2026
StartActual
Aug 5, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07489625
Lead sponsor
Qinghai Red Cross Hospital
Responsible party
Sponsor
First posted
Mar 24, 2026
Start date
Aug 5, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Aug 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydromorphone

Start the discussion